title: Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer.
abstract: Genistein is an isoflavone found in soy, and its chemo-preventive and -therapeutic effects have been well established from in vitro studies. Recently, however, its therapeutic actions in vivo have been questioned due to contradictory reports from animal studies, which rely on rodent models or implantation of cell lines into animals. To clarify in vivo effects of genistein in advanced prostate cancer patients, we developed a patient-derived prostate cancer xenograft model, in which a clinical prostatectomy sample was grafted into immune deficient mice. Our results showed an increased lymph node (LN) and secondary organ metastases in genistein-treated mice compared to untreated controls. Interestingly, invasive malignant cells aggregated to form islands/micrometastasis only in the secondary organs of the genistein-treated groups, not in the untreated control group. To understand the underlying mechanism for metastatic progression, we examined cell proliferation and apoptosis on paraffin-sections. Immunohistological data show that tumors of genistein-treated groups have more proliferating and fewer apoptotic cancer cells than those of the untreated group. Our immunoblotting data suggest that increased proliferation and metastasis are linked to enhanced activities of tyrosine kinases, EGFR and its downstream Src, in genistein-treated groups. Despite the chemopreventive effects proposed by earlier in vitro studies, the cancer promoting effect of genistein observed here suggests the need for careful selection of patients and safer planning of clinical trials.
authors: Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
authors: Hisae
authors: H
authors: Nakamura
authors: Yuwei
authors: Y
authors: Wang
authors: Takeshi
authors: T
authors: Kurita
authors: Hans
authors: H
authors: Adomat
authors: Gerald R
authors: GR
authors: Cunha
authors: Yuzhuo
authors: Y
authors: Wang
references: Cancer Res. 2009 Apr 15;69(8):3695-703
references: 19351854
references: Nutr Cancer. 1997;28(3):236-47
references: 9343831
references: Cancer Res. 1997 Mar 15;57(6):1199-205
references: 9067293
references: J Clin Oncol. 2005 Nov 10;23(32):8225-31
references: 16278477
references: Proc Soc Exp Biol Med. 1998 Mar;217(3):369-78
references: 9492350
references: CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
references: 4625049
references: Oncogene. 1989 Feb;4(2):145-51
references: 2564657
references: J Natl Cancer Inst. 1968 Jan;40(1):43-68
references: 5635018
references: Int J Oncol. 1999 Sep;15(3):525-33
references: 10427135
references: Oncogene. 2005 Nov 14;24(50):7443-54
references: 16288291
references: Am J Clin Nutr. 1984 Sep;40(3):569-78
references: 6383008
references: Can J Urol. 1997 Jun;4(2 Supp 1):22-27
references: 12735830
references: Cancer. 1989 Aug 1;64(3):598-604
references: 2743254
references: Nutr Cancer. 1998;32(3):123-31
references: 10050261
references: Environ Health Perspect. 1995 Oct;103 Suppl 7:103-12
references: 8593855
references: BMC Cancer. 2008 May 11;8:132
references: 18471323
references: Leuk Res. 1994 Jun;18(6):431-9
references: 8207961
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Obstet Gynecol. 1996 May;87(5 Pt 2):897-904
references: 8677131
references: J Nutr Biochem. 2006 Mar;17(3):204-10
references: 16198100
references: EMBO J. 2000 Oct 16;19(20):5406-17
references: 11032808
references: Neoplasia. 2004 Jul-Aug;6(4):354-63
references: 15256057
references: BMC Cancer. 2007 Jan 09;7:4
references: 17212824
references: Mol Cancer Ther. 2004 Oct;3(10):1271-9
references: 15486194
references: Cancer Res. 2008 Mar 15;68(6):2024-32
references: 18339885
references: Nutr Cancer. 1999;34(1):12-9
references: 10453436
references: Oncology. 2009;77(6):400-10
references: 20130423
references: Cell. 1987 Sep 11;50(6):823-9
references: 3113737
references: Prostate. 2005 Jul 1;64(2):149-59
references: 15678503
references: Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1213-21
references: 14652284
references: Nutr Cancer. 1998;31(3):184-91
references: 9795970
references: J Biol Chem. 1987 Apr 25;262(12):5592-5
references: 3106339
references: Ann N Y Acad Sci. 2006 Nov;1089:194-200
references: 17261767
references: Endocrinology. 1998 Oct;139(10):4252-63
references: 9751507
references: Toxicology. 1992 Sep;74(2-3):135-49
references: 1387742
references: CA Cancer J Clin. 2007 Jul-Aug;57(4):190-205
references: 17626117
references: Lancet. 1993 Nov 13;342(8881):1209-10
references: 7901532
references: Nutr Cancer. 2004;48(2):160-70
references: 15231450
references: Cancer Res. 1994 Jun 15;54(12):3260-6
references: 7911396
references: Lancet. 1991 May 18;337(8751):1197-200
references: 1673746
references: Lab Invest. 2005 Nov;85(11):1392-404
references: 16155594
references: Life Sci. 2003 Dec 26;74(6):733-42
references: 14654166
references: EMBO J. 1999 Sep 1;18(17):4608-18
references: 10469641
references: Prostate. 2003 Feb 15;54(3):169-80
references: 12518321
references: Cancer Cell. 2003 Sep;4(3):167-74
references: 14522250
references: Cell. 1990 Apr 20;61(2):203-12
references: 2158859
references: BJU Int. 2002 Jul;90(2):162-73
references: 12081758
references: Nutr Cancer. 1999;35(2):130-6
references: 10693166
references: J Steroid Biochem Mol Biol. 1993 May;45(5):399-405
references: 8499347
references: Oncol Rep. 2000 Jan-Feb;7(1):3-12
references: 10601582
references: Endocrinology. 2010 Jun;151(6):2433-42
references: 20375184
references: Oncogene. 1995 Oct 5;11(7):1383-8
references: 7478560
references: J Natl Cancer Inst. 1991 Apr 17;83(8):541-6
references: 1672382
references: Nat Rev Cancer. 2001 Oct;1(1):34-45
references: 11900250
references: Bioorg Med Chem. 2009 Apr 15;17(8):3152-61
references: 19321350
references: Cancer Gene Ther. 2008 Jul;15(7):413-48
references: 18404164
references: Endocrinology. 1978 Nov;103(5):1860-7
references: 570914
references: Int J Cancer. 2007 Jun 1;120(11):2491-8
references: 17304503